首页 | 本学科首页   官方微博 | 高级检索  
     


Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
Authors:Suhendan Ekmekcioglu PhD  Gerald S. Falchook MD  Aung Naing MD  FACP  Jennifer J. Wheler MD  Siqing Fu MD  PhD  Stacy L. Moulder MD  Sarina Piha‐Paul MD  Apostolia M. Tsimberidou MD  YueJin Wen MD  PhD  Kirk S. Culotta PharmD  Kenna Anderes MD  Darren W. Davis PhD  Wen Liu MD  Goldy C. George PhD  Luis H. Camacho MD  Susan Percy Ivy MD  Razelle Kurzrock MD
Affiliation:1. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas;4. Apocell Molecular Profiling and Diagnostics, Houston, Texas;5. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland;6. Division of Hematology and Oncology, Moores Cancer Center, University of California at San Diego, San Diego, California
Abstract:
Keywords:angiogenesis  phase 1  bevacizumab  cediranib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号